News releases
53 of 53 items
Robert Mansfield Appointed as Chief Executive Officer 11 Sep 2006
Neuropharm Group plc, the speciality pharmaceutical group focused on products for the treatment and management of developmental and degenerative disorders, is pleased to announce the appointment of Robert Mansfield as Chief Executive Officer, with immediate effect.
Neuropharm completes initial £700,000 fundraising 22 Jun 2006
Neuropharm Ltd, the speciality pharmaceutical group focused on products for the treatment and management of developmental and degenerative disorders, is pleased to announce that it has raised £700,000 by way of a subscription for ordinary shares of £1.00 each.
Neuropharm Granted Option on Orphan Drug Designation for Use of fluoxetine for the Treatment of Autism from Mount Sinai School of Medicine 26 May 2006
Neuropharm Ltd, the speciality pharmaceutical group focused on products for the treatment and management of developmental and degenerative disorders, is pleased to announce it has entered into an option agreement with Mount Sinai School of Medicine, New York, for the right to purchase the Orphan Drug Designation for the use of fluoxetine in the treatment of Autism.
53 of 53 items